- Ortho's VITROS® SARS-CoV-2 Antigen Test is the first high-volume COVID-19 antigen test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA). - With utility for mass-scale ...

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 ...

RARITAN, N.J., Oct. 24 /PRNewswire/ -- Ortho Clinical Diagnostics today announced 510(k) clearance from the United States Food and Drug Administration (FDA) for its VITROS(R) 5600 Integrated System.

RARITAN, N.J., July 21 Ortho Clinical Diagnostics today announced the U.S. Food and Drug Administration (FDA) approval of the VITROS((R)) Anti-HCV assay for use on the VITROS 5600((R)) Integrated and ...

Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, has submitted a premarket approval (PMA) application to the US Food and Drug Administration (FDA) for the Vitros ...

- Ortho's new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune ...

The FDA approved Ortho Clinical Diagnostics’ Vitros fourth-generation HIV combination test, which detects both HIV-1 and HIV-2 antibodies and the p24 antigen, which the company says allows it to ...

RARITAN, New Jersey, June 12, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, ...